Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Victor Ambros, Gary Ruvkun, David Baulcombe

Premium

University of Massachusetts Medical School researcher Victor Ambros has been named a co-recipient of the 2014 Gruber Genetics Prize along with Harvard Medical School's Gary Ruvkun and University of Cambridge's David Baulcombe for their pioneering work on microRNAs and siRNAs.

It was Ambros who in 1989 led work that identified the first miRNA. That research was later expanded upon in collaboration with Ruvkun, who helped show that the small, non-coding RNA repressed specific gene targets.

Baulcombe made similar discoveries in plants, identifying small RNAs involved in viral defense, transposable elements, and gene expression. His work helped lay the foundation for the discovery of RNA interference.

The Gruber Genetics Prize includes a $500,000 unrestricted cash award, which will be presented to this year's recipients at the annual meeting of the American Society of Human Genetics in October.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.